Advertisement

Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation

  • Gregory Y.H. Lip
    Correspondence
    Requests for reprints should be addressed to Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, England, UK
    Affiliations
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England, UK
    Search for articles by this author
Published:September 30, 2010DOI:https://doi.org/10.1016/j.amjmed.2010.05.007

      Abstract

      There is increasing recognition of the value of oral anticoagulation for stroke prevention in atrial fibrillation, as well as the availability of new oral anticoagulants that overcome the limitations of warfarin, implying that even more atrial fibrillation patients will be using oral anticoagulation, with the role of aspirin being less defined. Thus, we need a paradigm shift so that stroke risk assessment can be simplified in the identification of those patients who are truly at low risk (ie, CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category] score=0) who could be treated with no antithrombotic therapy, and all others (ie, CHA2DS2-VASc score ≥1), would be considered for oral anticoagulation. A simple bleeding risk assessment can clearly help guide office management here. The new HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio, Elderly, Drugs/alcohol concomitantly) bleeding risk schema has been proposed as a simple, easy calculation to assess bleeding risk in atrial fibrillation patients, whereby a score of ≥3 indicates “high risk” and some caution and regular review of the patient is needed, following the initiation of antithrombotic therapy, whether with oral anticoagulation or antiplatelet therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hughes M.
        • Lip G.Y.
        Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
        Thromb Haemost. 2008; 99: 295-304
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • Boechler M.
        • Rich M.W.
        • Radford M.J.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Lip G.Y.H.
        • Halperin J.
        Improving stroke risk stratification in atrial fibrillation.
        Am J Med. 2010; 123: 484-488
        • Wan Y.
        • Heneghan C.
        • Perera R.
        • et al.
        Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.
        Circ Cardiovasc Qual Outcomes. 2008; 1: 84-91
        • Morgan C.L.
        • McEwan P.
        • Tukiendorf A.
        • Robinson P.A.
        • Clemens A.
        • Plumb J.M.
        Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.
        Thromb Res. 2009; 124: 37-41
        • Mant J.
        • Hobbs F.D.
        • Fletcher K.
        • et al.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
        Lancet. 2007; 370: 493-503
        • Palareti G.
        • Cosmi B.
        Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients.
        Thromb Haemost. 2009; 102: 268-278
        • Shireman T.I.
        • Howard P.A.
        • Kresowik T.F.
        • Ellerbeck E.F.
        Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
        Stroke. 2004; 35: 2362-2367
        • Gage B.F.
        • Yan Y.
        • Milligan P.E.
        • et al.
        Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).
        Am Heart J. 2006; 151: 713-719
        • Beyth R.J.
        • Quinn L.M.
        • Landefeld C.S.
        Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.
        Am J Med. 1998; 105: 91-99
        • Kuijer P.M.
        • Hutten B.A.
        • Prins M.H.
        • Buller H.R.
        Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.
        Arch Intern Med. 1999; 159: 457-460
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey.
        Chest. 2010;Mar 18; ([Epub ahead of print])
        • Lip G.Y.H.
        Anticoagulation therapy and the risk of stroke in patients with Atrial Fibrillation at 'moderate risk' [CHADS2 score = 1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.
        Thromb Haemost. 2010; 4: 683-685
        • Sato H.
        • Ishikawa K.
        • Kitabatake A.
        • et al.
        Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
        Stroke. 2006; 37: 447-451
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Stroke Prevention in Atrial Fibrillation investigators
        A differential effect of aspirin in prevention of stroke on atrial fibrillation.
        J Stroke Cerebrovasc Dis. 1993; 3: 181-188
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151